News

Archive: 2020

DOD Awards University of Louisville $8.5 Million for COVID-19 Q-Griffithsin Repurposing Effort
December 9, 2020 — The JPM CBRN Medical leveraged an academic partnership to study the repurposing of a compound that shows promise against COVID-19... MORE

JPM CBRN Medical Tiger Team Takes Bold Action to Support Pandemic Response
December 4, 2020 — It is difficult to remember a time when “coronavirus” was not a part of our day-to-day vocabulary. The COVID-19 pandemic emerged from the shadows and threw the world into a tailspin, demanding ingenuity and resourcefulness as it pushed worldwide healthcare systems to their limits. As nations quickly scrambled to adapt and respond to the global... MORE

DOD-Funded Drug Remdesivir Receives FDA Approval for COVID-19 Treatment
December 1, 2020 — Yesterday, the U.S. Food and Drug Administration (FDA) approved Gilead Sciences, Inc.’s Veklury® (Remdesivir) for treatment of hospitalized COVID-19 patients who are 12 years of age or older and weigh at least 40 kilograms (88 lbs). The approval of Veklury® was supported by the agency’s analysis of data from three randomized, controlled clinical... MORE

SAB Biotherapeutics Awarded $57.5M from BARDA and U.S. Department of Defense for Manufacturing of SAB-185 for the Treatment of COVID-19
November 30, 2020 — SIOUX FALLS, S.D.--SAB Biotherapeutics (SAB), a clinical stage biopharmaceutical company developing a novel immunotherapy platform to produce specifically targeted, high-potency, fully human polyclonal antibodies without the need for human serum, today announced that, as part of Operation Warp Speed, the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services, and the Department of Defense Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) have awarded SAB $57.5 million in expanded scope for its DiversitAb™ Rapid Response Antibody Program contract for the manufacturing of SAB-185, the company’s clinical stage therapeutic candidate for COVID-19... MORE

DOD Awards Partner Therapeutics $35 Million for Repurposing and Emergency Use of Leukine for COVID-19 Treatment
August 4, 2020 — The JPM CBRN Medical leveraged an industry partnership to accelerate the repurposing of an FDA-approved drug for COVID-19 treatment research... MORE

JBADS Lite: Decon at the Speed of Relevance
July 30, 2020 — On March 11, 2020, the World Health Organization declared a pandemic when the coronavirus wreaked havoc across the world. SARS CoV-2, the virus that causes COVID-19, is easily transmitted through respiratory droplets causing over nine million people to become infected and has taken the lives of 477,000 people, to date worldwide. Due to the ease of... MORE

Joint Biological Aircraft Decontamination System Lite

DOD Awards Johns Hopkins University $35 Million for COVID-19 Convalescent Plasma Research
July 30, 2020 — The JPEO-CBRND used existing contract capabilities to accelerate COVID-19 clinical trials... MORE

DOD Awards Industry Partner Immunome $13.3 Million for Biosynthetic Convalescent Plasma Development
July 28, 2020 — The JPM CBRN Medical leveraged an industry partnership to accelerate COVID-19 prevention and treatment research... MORE

MRI Global to Deliver Three Mobile Medical Labs with $2 Million DOD Contract
May 1, 2020 — Three ATHENA Mobile Medical Labs to Arrive at Aberdeen Proving Ground, Edgewood Area ABERDEEN PROVING GROUND, EDGEWOOD AREA, Md. – May 1, 2020 – The Department of Defense (DOD) awarded a contract valued at over $2 million with MRI Global to procure three ATHENA Next Generation Mobile Laboratories for COVID-19 sample processing and testing.The Joint... MORE

DOD OTA Agreement Leveraged by Interagency for COVID-19 Rapid Response
April 10, 2020 — ABERDEEN PROVING GROUND, EDGEWOOD AREA, MD. – A Department of Defense (DOD) team led by the U.S. Air Force Agile Combat Support Program Executive Office Directorate (PEO ACS) leveraged an existing Other Transaction Authority (OTA) agreement within the Countering Weapons of Mass Destruction (CWMD) Consortium to award a Negatively Pressured Conex... MORE

News Search

News Archive - Search by Year and Month

2024 (37)
2023 (36)
2022 (31)
2021 (37)
2020 (15)
December (3)
November (1)
August (1)
July (3)
May (1)
April (1)
March (4)
February (1)
2019 (11)
2018 (5)
2017 (9)
2016 (1)

JPEO-CBRND Press Kit

Download our press kit, which includes helpful documents to better understand our work, such as – Command Brief, Chemical Biological Defense Program's Enterprise strategy, the JPEO-CBRND's Capabilities Catalog, Leadership Biographies, COVID-19 fact sheets, and contracting overview documents.

JPEO-CBRND Public Affairs Office

The JPEO-CBRND Public Affairs Office coordinates and responds to all public affairs and media relations needs on behalf of the JPEO-CBRND. To request a speaker, subject matter expert, or for other interview or request for comment please email our Public Affairs Office email below.